COQ2 nephropathy: a treatable cause of nephrotic syndrome in children

Background Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q 10 (CoQ 10 ) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ 10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem di...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 2018-07, Vol.33 (7), p.1257-1261
Hauptverfasser: Starr, Michelle C., Chang, Irene J., Finn, Laura S., Sun, Angela, Larson, Austin A., Goebel, Jens, Hanevold, Coral, Thies, Jenny, Van Hove, Johan L. K., Hingorani, Sangeeta R., Lam, Christina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q 10 (CoQ 10 ) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ 10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem disease. Case-Diagnosis/Treatment We report three pediatric patients with COQ2 variants presenting with nephrotic syndrome. Two of these patients had normal leukocyte CoQ 10 levels prior to treatment. Pathologic findings varied from mesangial sclerosis to focal segmental glomerulosclerosis, with all patients having abnormal appearing mitochondria on kidney biopsy. In two of the three patients treated with CoQ 10 supplementation, the nephrotic syndrome resolved; and at follow-up, both have normal renal function and stable proteinuria. Conclusions COQ2 nephropathy should be suspected in patients presenting with nephrotic syndrome, although less common than disease due to mutations in NPHS1 , NPHS2 , and WT1 . The index of suspicion should remain high, and we suggest that providers consider genetic evaluation even in patients with normal leukocyte CoQ 10 levels, as levels may be within normal range even with significant clinical disease. Early molecular diagnosis and specific treatment are essential in the management of this severe yet treatable condition.
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-018-3937-z